GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Atea Pharmaceuticals
Atea Pharmaceuticals is a biotech company developing antiviral drugs. Its stock price reflects the rise and fall of its COVID-19 treatment candidate. The chart is an example of binary risk in biotech, where a failure in a key study can send the stock plummeting.
Share prices of companies in the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing oral antiviral drugs for the treatment of a wide range of viral infections. We've categorized it as a "Pharma: Viruses" company, and the chart below shows how investors value companies in this important field.
Broad Market Index - GURU.Markets
Atea Pharmaceuticals is a biopharmaceutical company focused on developing oral antiviral drugs for the treatment of a wide range of viral infections. It is a component of the GURU.Markets index. The chart below shows the market. See how Atea shares compare to the healthcare sector.
Change in the price of a company, segment, and market as a whole per day
AVIR - Daily change in the company's share price Atea Pharmaceuticals
The daily fluctuations of Atea, a biopharmaceutical company, reflect the inherent volatility of the sector. change_co measures the reaction to antiviral drug trial data. This metric is important for analyzing risks and opportunities in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
Atea Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with AVIR, which focuses on antiviral drugs, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Atea is a biopharmaceutical company specializing in drugs to treat viral diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Atea's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Atea Pharmaceuticals
For Atea Pharmaceuticals, its year-over-year performance is a story of finding breakthroughs in treating viral diseases like COVID-19 and hepatitis C. Its 12-month market cap is entirely dependent on clinical trial data. Any success could lead to explosive growth, but research failures deal a serious blow to its valuation.
Annual dynamics of market capitalization of the market segment - Pharma virus
Atea Pharmaceuticals, Inc. is a clinical-stage biotech company specializing in the development of antiviral drugs. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this important area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atea Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Atea Pharmaceuticals
Atea, a biopharmaceutical company, has a speculative market capitalization. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its antiviral drug clinical trials, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing oral antiviral drugs for the treatment of a wide range of viral infections. The chart below reflects the general sentiment in the antiviral pharmaceutical sector, where there is always a need for new, effective medications.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs. Its shares are steeped in the world of clinical trials. Any news about the success or failure of its candidates can cause sharp fluctuations, completely ignoring overall market trends. It's a bet on science in the fight against infectious diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Atea Pharmaceuticals
Shares of Atea Pharmaceuticals, a biopharmaceutical company focused on antiviral drugs, are extremely volatile. Weekly price movements depend entirely on the results of clinical trials of their candidates for various viral diseases. The chart below illustrates how short-term scientific events shape biotech valuations.
Weekly dynamics of market capitalization of the market segment - Pharma virus
How does Atea Pharmaceuticals' performance compare to the broader biotech sector? This chart compares the antiviral company's weekly stock price movements to the overall trend. This helps us understand whether its move, driven by clinical trial news, is a unique event or reflects broader sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Atea Pharmaceuticals is a biotech company developing antiviral drugs. This chart compares its weekly performance to the market. It shows how disconnected its stock is from the macroeconomic environment and entirely dependent on clinical trial successes and pandemic news.
Market capitalization of the company, segment and market as a whole
AVIR - Market capitalization of the company Atea Pharmaceuticals
The price chart of Atea Pharmaceuticals tells the story of the rise and fall of hopes for its oral COVID-19 drug. The company's market cap, once considered a frontrunner in this race, now depends on its ability to refocus its antiviral platform on other diseases. The dynamics illustrate the risks of biotech.
AVIR - Share of the company's market capitalization Atea Pharmaceuticals within the market segment - Pharma virus
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company whose market share is based on its antiviral drug development. Its market capitalization reflects both the potential of its research and the setbacks of its COVID-19 program.
Market capitalization of the market segment - Pharma virus
This chart is a barometer of the biotech sector focused on antiviral drugs. Atea Pharmaceuticals is one of the developers in this field. Fluctuations in the chart reflect the successes and failures of clinical trials, which determine the fate of this entire segment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a market valuation of the fight against viral threats. Atea Pharmaceuticals' market cap is a bet on its antiviral drug development platform. The chart shows how the biotech company, which targets diseases like hepatitis C and COVID-19, is shaping its share of the global healthcare economy.
Book value capitalization of the company, segment and market as a whole
AVIR - Book value capitalization of the company Atea Pharmaceuticals
The book value of Atea Pharmaceuticals, a clinical-stage company, is determined by its scientific potential. The chart below reflects the financial valuation of its antiviral drug intellectual property. The dynamics illustrate how the company invests in clinical research, building its core asset.
AVIR - Share of the company's book capitalization Atea Pharmaceuticals within the market segment - Pharma virus
For Atea Pharmaceuticals, a biopharmaceutical company focused on antiviral drugs, its tangible assets are its advanced laboratories and scientific equipment. The chart shows the company's share of this highly specialized scientific infrastructure, which forms the physical basis for fighting viral infections.
Market segment balance sheet capitalization - Pharma virus
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Atea, which develops antiviral drugs, looks like a "lightweight." Its value lies in its patents and scientific data, not in its large factories. Its business is science, not mass production.
Book value of all companies included in the broad market index - GURU.Markets
Atea Pharmaceuticals is a biotech company developing antiviral drugs. Its assets are not its manufacturing plants, but rather its intellectual property and clinical trial data. The company's balance sheet is the value of its scientific approach to combating viruses that pose a real threat to health and the economy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Atea Pharmaceuticals
Atea's balance sheet is its cash. Its market capitalization, close to the value of this cash, shows that investors have completely written off its antiviral developments after the failure of its COVID-19 drug. The MvsBCap_Co chart ≈ 1 indicates the company's "cash piggy bank" valuation.
Market to book capitalization ratio in a market segment - Pharma virus
Atea Pharmaceuticals is a biotech company developing antiviral drugs. The chart shows the speculative valuation of its research and development pipeline, which is heavily dependent on clinical trial results and news about viral outbreaks.
Market to book capitalization ratio for the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections. Its value is determined by the success of its clinical programs. This chart shows how the market values biotech companies working to address pressing public health challenges.
Debts of the company, segment and market as a whole
AVIR - Company debts Atea Pharmaceuticals
For Atea Pharmaceuticals, a biopharmaceutical company focused on antiviral drugs, debt is a source of funding for R&D. This chart shows how the company raises capital to conduct clinical trials of its candidates for diseases like hepatitis C. In this industry, debt is an investment in the fight against viral threats.
Market segment debts - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs for the treatment of severe infections. The COVID-19 pandemic has highlighted the importance of this area. This chart shows how the clinical-stage company is funding its expensive research and development in this critical area of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company specializing in antiviral drugs. This chart shows its reliance on debt to finance lengthy and expensive clinical trials. A high debt load for a company in the development stage is a huge risk that can only be justified if its key drug is successful.
Market segment debt to market segment book capitalization - Pharma virus
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral drugs. Financing clinical trials requires significant capital. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Atea Pharmaceuticals (AVIR) is a clinical-stage biopharmaceutical company focused on developing antiviral drugs. This chart shows the overall debt burden of the economy. It serves as a contrast to Atea's financial model, which, like most biotech companies in the R&D phase, relies on equity rather than bank loans.
P/E of the company, segment and market as a whole
P/E - Atea Pharmaceuticals
For Atea Pharmaceuticals, a biopharmaceutical company developing antiviral drugs, this chart reflects its scientific prospects. The price-to-earnings ratio is likely nonexistent. The company's valuation soared during the pandemic on hopes for a COVID-19 treatment. Now its value depends on the success of other developments in its pipeline.
P/E of the market segment - Pharma virus
Here's the average P/E for biotech companies. For Atea Pharmaceuticals, which develops antiviral drugs, it serves as a benchmark. It reflects the overall level of optimism in the sector post-pandemic, providing context for Atea's valuation as it seeks new growth drivers following the failure of its COVID-19 drug.
P/E of the market as a whole
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections such as COVID-19 and hepatitis C. This risk appetite chart helps understand how investors value biotech companies in the infectious disease field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections. This graph reflects expectations for its scientific platform. The valuation is heavily dependent on the results of clinical trials of its candidates and the potential demand for new treatments for viral diseases, such as hepatitis C or COVID-19.
%20P%2FE%20Atea%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Atea-Pharmaceuticals&v=1772621349614 "Chart of the company's future (projected) P/E Atea Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company specializing in the development of antiviral drugs. This chart reflects the company's long-term profitability expectations. It shows how the market views their scientific platform and their ability to develop effective treatments for diseases such as hepatitis C or COVID-19.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772621349700 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs. Its success depends on the results of clinical trials and the epidemiological situation. This graph of general market expectations influences Atea through the overall assessment of the biotech sector and investor willingness to fund the fight against infectious diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772621349744 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs for the treatment of a wide range of viral infections. Its financial results reflect the costs of clinical trials in the hopes of developing effective treatments against threats such as COVID-19 and hepatitis C.
Profit of companies in the market segment - Pharma virus
Atea Pharmaceuticals develops antiviral drugs. Its financial performance, like that of many biotech companies, reflects high R&D expenditures. This chart for the pharmaceutical industry illustrates how the constant need for new treatments for viral threats drives R&D investment, shaping the sector's future profitability.
Overall market profit
Atea Pharmaceuticals is a biotech company developing antiviral drugs. Its success depends on the results of clinical trials and the emergence of epidemiological threats. This makes its business unpredictable and unrelated to traditional economic cycles. Its shares can soar on news of a new virus or a successful trial.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Atea Pharmaceuticals
Atea Pharmaceuticals is a biotech company focused on developing antiviral drugs. This timeline reflects expectations, which depend on the success of its clinical programs, particularly following the failure of its COVID-19 drug. Forecasts will evolve as data on other viral diseases becomes available.
%20profit%20of%20the%20company%20Atea%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Atea-Pharmaceuticals&v=1772621349897 "Graph of future (projected) profit of the company Atea Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs. This chart shows the revenue forecast for the entire antiviral pharmaceutical sector. It reflects expected demand for new treatments for viral infections. This context is key for assessing the potential of Atea's clinical programs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772621349927 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs. Its success depends on the results of clinical trials and the emergence of epidemiological threats. The overall economic forecasts presented here influence it through the level of government funding for infectious disease programs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772621349976 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biotech focused on developing antiviral drugs for diseases such as COVID-19 and hepatitis C. This chart shows how investors are valuing its scientific platform after the COVID-19 drug setback, placing their bets on its other pipeline.
P/S market segment - Pharma virus
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections, such as COVID-19 and hepatitis C. This chart shows the average valuation in the sector, helping to understand how the market views Atea's scientific platform and drug candidates.
P/S of the market as a whole
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral drugs for diseases such as COVID-19 and hepatitis C. This market valuation chart helps understand how investors view the biotech, whose revenue depends on the success of clinical trials and potential pandemics.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral drugs. Its valuation is entirely dependent on the success of clinical trials. This chart reflects investor expectations for its developments and their potential future sales if approved.
%20P%2FS%20Atea%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Atea-Pharmaceuticals&v=1772621350214 "The graph of the company's future (projected) P/S Atea Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs. This chart compares market expectations for its future revenue with those of other antiviral drug makers. This estimate reflects investor expectations for the success of its clinical programs for diseases such as COVID-19 and hepatitis C.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772621350233 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Atea Pharmaceuticals is a biotech company developing antiviral drugs. Its success depends on the results of clinical trials. The overall market optimism reflected in this chart creates a favorable environment for raising the capital needed to advance innovative drugs through the long and costly development process.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772621350283 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs for the treatment of diseases such as COVID-19 and hepatitis C. Currently in the clinical stage, its revenue comes from partnerships and grants. The chart shows the financial flows that enable the company to conduct research into viral infections.
Sales of companies in the market segment - Pharma virus
Atea Pharmaceuticals is a biotech company focused on developing antiviral drugs for the treatment of severe infectious diseases. Its approach is based on the creation of small-molecule drugs that can be administered orally. This graph illustrates the need for new antiviral agents, especially after the pandemic, and the investment interest in this area.
Overall market sales
Atea Pharmaceuticals is a biopharmaceutical company focused on antiviral drugs. Its success depends on the results of clinical trials and the epidemiological situation. The connection to economic cycles reflected in this chart is minimal, but overall market conditions influence the company's ability to raise capital for research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs for the treatment of severe viral infections. The company gained notoriety during the pandemic for its work on a COVID-19 treatment. This chart reflects analyst expectations for the success of its clinical programs and the potential of new antiviral agents.
%20sales%20of%20the%20company%20Atea%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Atea-Pharmaceuticals&v=1772621350422 "Schedule of future (projected) sales of the company Atea Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company specializing in the development of antiviral drugs. This chart shows general forecasts for the pharmaceutical industry. It allows one to assess the potential of the company's platform for developing new drugs against a wide range of viral infections, including hepatitis C and COVID-19.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772621350464 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs. This chart, reflecting healthcare costs and pandemic preparedness, is important to the company. Awareness of global risks following COVID-19 and a stable economic environment provide funding for the development of new treatments for viral infections.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772621350553 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral drugs. Its core business is scientific research and clinical trials. This chart illustrates the significant investment in R&D, which is essential for the development of new drugs to combat viral infections.
Market segment marginality - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company developing antiviral drugs for the treatment of severe infections. Their future profitability will depend on the success of clinical trials and the ability to bring an effective drug to market. This chart currently reflects their investment in research and development (R&D).
Market marginality as a whole
Atea Pharmaceuticals is a biotech company developing antiviral drugs. The overall profitability picture is irrelevant for them. After the failure of their COVID-19 drug, their future depends on the success of other programs in their portfolio. This is a high-risk bet on a scientific breakthrough in the treatment of viral diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Atea Pharmaceuticals
Atea Pharmaceuticals is a biotech company specializing in antiviral drug development. This graph shows the team's scientific staff. Headcount dynamics can fluctuate and reflect both clinical trial progress and setbacks, which is typical in this sector.
Share of the company's employees Atea Pharmaceuticals within the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections. This chart shows its market share in the pharmaceutical sector. It reflects the team of scientists working on developing new oral drugs that could transform the treatment of diseases like COVID-19.
Number of employees in the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs. This chart illustrates employment in the pharmaceutical industry. The dynamics of headcount, especially since the pandemic, reflect the successes and failures of clinical trials, which are key for companies operating in this high-risk field.
Number of employees in the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs for the treatment of severe viral infections, including hepatitis C and COVID-19. This chart illustrates the overall labor market, and the pharmaceutical sector, represented by Atea, is one of the most research-intensive, constantly requiring highly qualified scientists to combat new health threats.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals, Inc. is a biopharmaceutical company developing antiviral drugs. During the development stage, its value is determined by its pipeline of potential drugs. This chart shows a high but volatile market capitalization per employee, as the market evaluates the likelihood of clinical trial success. This is a classic example of an R&D-driven biotech business.
%20of%20the%20company%20Atea%20Pharmaceuticals%20(AVIR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Atea-Pharmaceuticals-AVIR&v=1772621350952 "Chart of market capitalization per employee (in thousands of dollars) of the company Atea Pharmaceuticals (AVIR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Seritage Growth Properties is a REIT created to repurpose and lease former Sears and Kmart stores. This metric reflects the value of its real estate portfolio per redevelopment team. The chart allows you to assess how successfully the company is transforming aging retail space into valuable assets.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772621350998 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs. Its value depends on the success of clinical trials. This graph will reflect the market's assessment of its scientific potential. The high cost per employee reflects investors' bet on the development of a new, effective drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772621351032 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals (AVIR) is a biopharmaceutical company developing antiviral drugs (e.g., for hepatitis C and COVID-19). This is R&D. This chart shows the "cost of science"—the negative profit (expenses) per scientist working on the development of new antiviral drugs.
%20Chart%20Atea%20Pharmaceuticals%20(AVIR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Atea-Pharmaceuticals-AVIR&v=1772621351121 "Company Profit Per Employee (in thousands of dollars) Chart Atea Pharmaceuticals (AVIR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Atea Pharmaceuticals is a biopharmaceutical company specializing in the development of oral antiviral drugs (COVID-19, hepatitis C). Their core business is R&D. This chart shows the benchmark for staff efficiency in biotech. It is important for assessing how effectively Atea's research team is using capital to create new antiviral drugs.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772621351167 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs (for example, for hepatitis C or COVID-19). This is a classic R&D business. The chart shows the investment (negative return) per scientist in the effort to discover and bring a new, effective antiviral drug to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772621351249 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals is a biopharmaceutical company focused on developing antiviral drugs. This chart reflects its clinical status. Revenue per employee can fluctuate significantly depending on research progress and partnerships with major pharmaceutical companies for co-development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Atea-Pharmaceuticals-AVIR&v=1772621351313 "Sales chart per company employee Atea Pharmaceuticals (AVIR)")
Sales per employee in the market segment - Pharma virus
Atea Pharmaceuticals (AVIR) is a clinical-stage biotech company specializing in the development of oral antiviral drugs (e.g., for COVID-19). This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform.
Sales per employee for the market as a whole
Atea Pharmaceuticals (AVIR) is a biotech company focused on developing antiviral drugs, specifically for the treatment of COVID-19 and hepatitis C. It is a clinical-stage R&D company. This graph (close to zero) reflects their model: the company invests in its own scientists to conduct clinical trials, and revenue (if any) comes from partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals is a biotech company developing antiviral drugs. The company gained notoriety during the pandemic, but its COVID-19 treatment failed. This chart shows bearish bets. The shorts are driven by this failure and doubts about the success of other developments in the company's portfolio.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Atea-Pharmaceuticals-AVIR&v=1772621351426 "Short Shares Chart for the Company Atea Pharmaceuticals (AVIR)")
Shares shorted by market segment - Pharma virus
Atea Pharmaceuticals (AVIR) is a clinical-stage biotech developing antiviral drugs, specifically for the treatment of COVID-19 and hepatitis C. This chart shows the bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism about AVIR's success following the failure of their flagship COVID drug.
Shares shorted by the overall market
Atea Pharmaceuticals (AVIR) is a clinical-stage biotech developing antiviral drugs. It's a risky bet on science. This market pessimism chart shows when investors are risk-averse. AVIR shares, with no revenue, sell off during periods of panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Atea-Pharmaceuticals-AVIR&v=1772621351601 "RSI 14 indicator chart for the company's stock Atea Pharmaceuticals (AVIR)")
RSI 14 Market Segment - Pharma virus
Atea Pharmaceuticals is a biotech company specializing in the development of antiviral drugs for the treatment of diseases such as hepatitis C and COVID-19. This sector is highly dependent on clinical trial data. This chart measures the overall momentum in the antiviral biotech sector. It helps us understand whether AVIR's momentum is a reaction to its data or general hype.
RSI 14 for the overall market
Atea Pharmaceuticals (AVIR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AVIR (Atea Pharmaceuticals)
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral drugs for the treatment of COVID-19, hepatitis C, and other viral threats. This chart reflects the collective opinion of experts: what average 12-month price they see for AVIR shares, which depends almost entirely on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AVIR-Atea-Pharmaceuticals&v=1772621351742 "A chart showing analyst consensus forecasts for the expected stock price. AVIR (Atea Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price AVIR (Atea Pharmaceuticals)
Atea (AVIR) is a biotech company focused on the R&D of oral antiviral drugs (from Hepatitis C to COVID-19). This chart shows the difference between analysts' target price and the current price. For an R&D company, it reflects the extent to which experts believe in the scientific success of its R&D pipeline, factoring into their forecasts the potential for new drug approvals that the market is currently ignoring.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AVIR-Atea-Pharmaceuticals&v=1772621351780 "A chart showing the difference between the consensus forecast and the actual stock price. AVIR (Atea Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Atea (AVIR) is a biotech company betting on oral antivirals. After failing with its COVID drug, the company focused on hepatitis C. It's a classic R&D story. This chart shows the overall analyst sentiment across the antiviral pharmaceutical sector. It reflects whether experts believe new breakthroughs are possible or whether they believe the industry has entered a post-pandemic lull.
Analysts' consensus forecast for the overall market share price
Atea Pharma is a biotech company working on antiviral drugs. It's a risky R&D venture that requires massive capital. This chart, which shows investors' overall risk appetite, is critical. During periods of optimism, the market is willing to burn cash, funding unprofitable biotechs. During periods of pessimism, there's risk aversion, and capital for AVIR dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Atea Pharmaceuticals
Atea (AVIR) is a clinical-stage biotech focused on developing oral (tablet) antiviral drugs for the treatment of serious diseases such as Hepatitis C and COVID-19. This graph represents pure R&D investment. Its valuation reflects the market's faith in their scientific platform and clinical trial data, which rivals giants like Pfizer and Gilead.
AKIMA Market Segment Index - Pharma virus
Atea Pharmaceuticals is a biotech company focused on developing antiviral drugs for diseases such as hepatitis C. In this field, operational efficiency is as important as scientific breakthroughs. This chart shows the average index for the entire pharmaceutical sector. It provides investors with a benchmark for how Atea's overall performance compares to the industry average.
The AKIM Index for the overall market
Atea Pharmaceuticals is a biotech company developing oral antiviral drugs for the treatment of severe viral infections (including COVID-19 and hepatitis C). This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such clinical trials with binary outcomes.
